期刊文献+

血清胸苷激酶1在宫颈癌患者预后以及复发评估中的意义 被引量:9

下载PDF
导出
摘要 目的:探讨宫颈癌患者血清胸苷激酶1(S-TK1)水平的变化情况与临床疗效以及复发评估的意义。方法:用免疫增强化学发光点印记法(ECLdot-blot)检测98例不同临床分期宫颈癌患者术前以及术后1周和术后1、3、6、12、18、24个月的S-TK1水平,观察其动态变化规律。结果:宫颈癌患者S-TK1水平显著高于正常对照者(P<0.05);宫颈癌不同分期的患者术后3个月S-TK1均较术前有明显下降;病情平稳者术后6个月S-TK1接近正常水平;术后12、18、24个月的S-TK1水平变化不大,差异无统计学意义(P>0.05);部分病情进展或复发患者于临床症状出现前1.5~3.1个月(平均1.8个月)出现S-TK1的再次上升。结论:S-TK1可以为宫颈癌的预后以及复发提供重要价值。
机构地区 南京第
出处 《实用医学杂志》 CAS 北大核心 2012年第13期2228-2230,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献8

二级参考文献24

  • 1吕晓娴,刘冰,张瑞丽.血清CEA和CA199及CA724联合检测对胃癌诊断的临床意义[J].中国肿瘤临床与康复,2007,14(1):26-28. 被引量:30
  • 2刘家云,陈名声,苏明权,于文彬,郝晓柯.血清胃蛋白酶原、促胃液素对胃癌的诊断价值[J].现代检验医学杂志,2007,22(3):19-21. 被引量:8
  • 3段秋林,李扬威,石峰,梅雄,郑伦和,段欣,吴健民.联合检测胃液中CEA、CA199、CA242在胃癌诊断中的应用价值[J].肿瘤防治研究,2007,34(8):607-609. 被引量:14
  • 4Brockenbrough J S, Rasey J S. A simple quantitative assay for the activity of thymidine kinase 1 in solid tumors [ J ]. Nuel Meal Biol, 2007, 34(6): 619.
  • 5Fabio Gasparri, Naining Wang, Sven Skog, et al. Thymidine kinase 1 expression defines an activated G1 state of the cell cy- cle as revealed with site- specific antibodies and ArrayScan as- says[J]. European Journal of Cell Biology, 2009, 88 (12): 779.
  • 6Munch- Petersen B, Cloos L, Jensen H K, et al. Human thymidine kinase 1 Regulation in normal and malignant cells [J]. Advances in Enzyme Regulation, 1995, 35: 69.
  • 7He Q, Wu J P, Mao R Y, et al. The clinical significance of thymidine kinase 1 measurement in patients with breast cancer using anti- TK1 antibody[J ]. European Journal of Cancer, 2001, 6: 178.
  • 8Karl - Heinz Kurth, Richard Sylvester J. Prognostic factors in non muscle - invasive bladder tumors [ J ]. European urology supplements, 2007, 6(14): 789.
  • 9Namiko Kuroiwa, Masao Nakayama, Tamotsu Fukuda, et al. Specific recognition of cytosolic thymidine kinase in the human lung tumor by moncelonal antibodies raised against recombi- nant human thymidine kinase[J ]. Journal of Immunological Methods, 2001, 253(1-2): 1.
  • 10Zhang J, Jiao Zou S. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical out- come of primary bladder carcinoma patients [J ]. Oncol Rep, 2006, 15(2): 4552.

共引文献26

同被引文献124

  • 1秦雷,杨林.血清胸苷激酶-1与鼻咽癌临床病理特征相关性分析[J].中华肿瘤防治杂志,2013,20(2):113-117. 被引量:7
  • 2陈向敏,夏克栋,林巧爱,董海艳,张丽芳.热休克蛋白70,p53,Bcl-2在宫颈癌组织中的表达及相关性研究[J].中国现代医学杂志,2005,15(2):253-255. 被引量:12
  • 3Ke PY,Hu CM,Chang YC,et al.Hiding human thymidine kinase 1 from APC/C-mediated destruction by thymidine binding[J].FASEB J,2007,21(4):1276-1284.
  • 4Pérez-Pérez MJ,Priego EM,Hernández AI,et al.Structure,physiological role,and specific inhibitors of human thymidine kinase 2 (TK2):present and future[J],Med Res Rev,2008,28(5):797-820.
  • 5Zhang J,Jia Q,Zou S,et al.Thymidine kinase 1:a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients[J].Oncol Rep,2006,15(2):455-461.
  • 6Chabes A,Thelander L.DNA building blocks at the foundation of better survival[J].Cell Cycle,2003,2 (3):171-173.
  • 7Munch-Petersen B.Reversible tetramerization of human TK1 to the high catalytic efficient form is induced by pyrophosphate,in addition to tripolyphosphates,or high enzyme concentration[J].FEBS J,2009,276(2):571-580.
  • 8Welin M,Kosinska U,Mikkelsen NE,et al.Structures of thymidine kinase 1 of human and mycoplasmic origin[J].Proc Natl Acad Sci U S A,2004,101(52):17970-17975.
  • 9Mao Y,Wu J,Wang N,et al.A comparative study:immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer[J].Cancer Invest,2002,20 (7-8):922-931.
  • 10He Q,Zou L,Zhang PA,et al.The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody[J].Int J Biol Markers,2000,15 (2):139-146.

引证文献9

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部